RECORD // Company

Actinium Pharmaceuticals, Inc.

Formerly: Cactus Ventures, Inc.

Built 2026-11-22T00:57:15Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
SEC EDGAR (1)
Records under a former name (1)

The name on these records was this company's name in the past (SEC name history). An old name can also belong to an unrelated organization, so they are shown apart and are not counted above.

Matched by name only, not merged (8)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • CACTUS VENTURES, LLC · Ct business · name equals 'Cactus Ventures' but other unrelated entities share it Possible match based on name, not a shared identifier. Compare the records. Compare
  • Actinium Pharmaceuticals · Ctgov · exact name match to 'Actinium Pharmaceuticals, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • Actinium Pharmaceuticals, Inc. · East licences · same registered legal name as 'Actinium Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Actinium Pharmaceuticals, Inc. · East licences · same registered legal name as 'Actinium Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • ACTINIUM PHARMACEUTICALS, INC. (lobbying via an individual registrant) · LDA lobbying · same registered legal name as 'Actinium Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • ACTINIUM PHARMACEUTICALS, INC. · Ny corps · same registered legal name as 'Actinium Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • CACTUS VENTURES LLC · Ny corps · name equals 'Cactus Ventures' but other unrelated entities share it Possible match based on name, not a shared identifier. Compare the records. Compare
  • ACTINIUM PHARMACEUTICALS, INC. · USAspending · same registered legal name as 'Actinium Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

4 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-16 · accession 0001213900-26-120788

ItemValuePeriodFormFiledAccessionReport
Revenue$35,000,0009 months ended 2026-09-3010-Q2026-11-160001213900-26-1207882026-11-22 00:57 UTCReport an error
Net income (loss)$-5,843,0003 months ended 2026-09-3010-Q2026-11-160001213900-26-1207882026-11-22 00:57 UTCReport an error
Cash and cash equivalents$28,677,000at 2026-09-3010-Q2026-11-160001213900-26-1207882026-11-22 00:57 UTCReport an error
Contract liabilities, noncurrent (from an earlier report)$35,000,000at 2026-03-3110-Q2026-05-080001213900-26-0539802026-11-22 00:57 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001388320
Ticker
ATNM
EIN
880378336
Record ID
sx:sec:0001388320

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

23 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-22 00:57 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-22 00:57 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-22 00:57 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-22 00:57 UTCReport an error
Business address100 PARK AVE., 23RD FLOOR, NEW YORK, NY, 100172026-11-16SEC EDGAR company profile2026-11-22 00:57 UTCReport an error
ExchangesNYSE2026-11-16SEC EDGAR company profile2026-11-22 00:57 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$90,0002025-12-3110-K, XBRL Revenues2026-11-22 00:57 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-33,887,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 00:57 UTCReport an error
Total assets (at 2025-12-31)$51,775,0002025-12-3110-K, XBRL Assets2026-11-22 00:57 UTCReport an error
Stockholders' equity (at 2025-12-31)$7,834,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 00:57 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$47,998,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 00:57 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-24,580,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 00:57 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$104,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 00:57 UTCReport an error
Operating lease liabilities (at 2024-12-31)$1,553,0002024-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 00:57 UTCReport an error
Form D total offering amount (D/A filed 2014-01-21)$6,636,7202014-01-21D/A2026-11-22 00:57 UTCReport an error
Form D total amount sold (D/A filed 2014-01-21)$6,636,7202014-01-21D/A2026-11-22 00:57 UTCReport an error
Form D industry groupPharmaceuticals2014-01-21D/A2026-11-22 00:57 UTCReport an error
Form D revenue rangeNo Revenues2014-01-21D/A2026-11-22 00:57 UTCReport an error
Form D date of first sale2013-12-272014-01-21D/A2026-11-22 00:57 UTCReport an error
8-K Item 5.02, Departure of Directors or Certain Officers; Election (filed 2026-10-15)of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. Appointment of Chief Financial Officer On October 14, 2026, Matt David, M.D., age 49, commenced service as Chief Financial Officer and principal financial officer of Actinium Pharmaceuticals, Inc. (the “Company”). The Company entered into an offer letter with Dr. David on September 30, 2026 (the “Offer Letter”). Dr. David brings more than 20 years of life sciences, corporate finance, capital markets and investor relations experience. He served as Chief Financial Officer of CorMedix Inc. from May 2020 to September 2025 and subsequently as its Chief Business Officer through October 2026. He was…2026-10-15SEC EDGAR 8-K 0001213900-26-109884 (text as filed, excerpt)2026-11-22 00:57 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-10-15)On October 15, 2026, the Company issued a press release announcing the appointment of Dr. David. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.2026-10-15SEC EDGAR 8-K 0001213900-26-109884 (text as filed, excerpt)2026-11-22 00:57 UTCReport an error
8-K Item 3.01, Notice of Delisting or Failure to Satisfy a Continued (filed 2026-08-14)Listing Rule or Standard; Transfer of Listing. As previously disclosed, on May 27, 2026, Actinium Pharmaceuticals, Inc. (the “Company”) received notice from NYSE American LLC (“NYSE American”) that the Company was not in compliance with the continued listing standards set forth in Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide (the “Company Guide”). The Company submitted a compliance plan to NYSE American on June 18, 2026. On August 12, 2026, the Company received a letter from NYSE Regulation stating that it had reviewed and accepted the Company’s compliance plan submitted on June 18, 2026 and granted the Company a plan period through November 27, 2027 (the “Plan Period”)…2026-08-14SEC EDGAR 8-K 0001213900-26-090232 (text as filed, excerpt)2026-11-22 00:57 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-08-14)On August 14, 2026, the Company issued a press release announcing NYSE Regulation’s acceptance of the Company’s compliance plan. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.2026-08-14SEC EDGAR 8-K 0001213900-26-090232 (text as filed, excerpt)2026-11-22 00:57 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.